LDLR and familial hyperaldosteronism: In addition, by systematically assessing the therapeutic effect of CNP‐produced EV‐AAV‐LDLR in a LDLR−/− FH mouse model, we confirmed the superior therapeutic efficacy and biological safety of a lower dose of EV‐AAV, and notably, it remains highly effective in the presence of pre‐existing immunity.